Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Nephrology
Volume 2014, Article ID 201568, 4 pages
http://dx.doi.org/10.1155/2014/201568
Case Report

Blockade of Alternative Complement Pathway in Dense Deposit Disease

1Service de Pharmacie, Hôpital Robert Debré, 48 boulevard Sérurier, 75019 Paris, France
2Service de Néphrologie, Centre Hospitalier Territorial de Nouvelle Calédonie, Gaston Bourret, BP J5, 98849 Nouméa, New Caledonia
3Service de Néphrologie Pédiatrique, Hôpital Robert Debré, 48 boulevard Sérurier, 75019 Paris, France
4Laboratoire d’Anatomopathologie, Hôpital Robert Debré, 48 boulevard Sérurier, 75019 Paris, France
5Laboratoire d’Immunologie, Hôpital Européen Georges-Pompidou, 20-40 rue Leblanc, 75015 Paris, France

Received 31 October 2013; Accepted 26 December 2013; Published 6 February 2014

Academic Editors: R. Enríquez, H. Matsukura, and K. Nozu

Copyright © 2014 Aurore Berthe-Aucejo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. J. H. Smith, J. Alexander, P. N. Barlow et al., “New approaches to the treatment of dense deposit disease,” Journal of the American Society of Nephrology, vol. 18, no. 9, pp. 2447–2456, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Sethi, J. D. Gamez, J. A. Vrana et al., “Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway,” Kidney International, vol. 75, no. 9, pp. 952–960, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Servais, L.-H. Noël, L. T. Roumenina et al., “Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies,” Kidney International, vol. 82, no. 4, pp. 454–464, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Martínez-Barricarte, M. Heurich, F. Valdes-Cañedo et al., “Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation,” Journal of Clinical Investigation, vol. 120, no. 10, pp. 3702–3712, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. G. B. Appel, H. T. Cook, G. Hageman et al., “Membranoproliferative glomerulonephritis type II (dense deposit disease): an update,” Journal of the American Society of Nephrology, vol. 16, no. 5, pp. 1392–1403, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Vivarelli, A. Pasini, and F. Emma, “Eculizumab for the treatment of dense-deposit disease,” New England Journal of Medicine, vol. 366, no. 12, pp. 1163–1165, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. A. S. Bomback, R. J. Smith, G. R. Barile et al., “Eculizumab for dense deposit disease and C3 glomerulonephritis,” Clinical Journal of the American Society of Nephrology, vol. 7, no. 5, pp. 748–756, 2012. View at Publisher · View at Google Scholar
  8. E. Daina, M. Noris, and G. Remuzzi, “Eculizumab in a patient with dense-deposit disease,” New England Journal of Medicine, vol. 366, no. 12, pp. 1161–1163, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Radhakrishnan, A. Lunn, M. Kirschfink et al., “Eculizumab and refractory membranoproliferative glomerulonephritis,” New England Journal of Medicine, vol. 366, no. 12, pp. 1165–1166, 2012. View at Publisher · View at Google Scholar · View at Scopus